使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics third-quarter 2026 conference call. (Operator Instructions) This call is being recorded today, Tuesday, November 10, 2026.
各位女士、先生,下午好,歡迎參加 Capricor Therapeutics 2026 年第三季財報電話會議。(接線員指示) 本次電話會議將於今天(2026 年 11 月 10 日,星期二)錄音。
I would now like to turn the conference over to CFO, AJ Bergmann, for the forward-looking statement. Please go ahead.
現在我想把會議交給財務長 AJ Bergmann,由他宣讀前瞻性聲明。請開始。
Anthony Bergmann - Chief Financial Officer
Anthony Bergmann - Chief Financial Officer
Thank you, and good afternoon. Before we begin, I'd like to remind you that any statements made during today's call are not historical and are considered to be forward-looking statements. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, our most recent quarterly reports on Form 10-Q as well as other reports filed with the SEC.
謝謝,各位下午好。在開始之前,我想提醒各位,今天電話會議中所作的任何陳述均非歷史事實,並被視為前瞻性陳述。由於各種重要因素,實際結果可能與這些陳述所示存在重大差異,包括我們最近一期 Form 10-K 年報的風險因素章節、最近的 Form 10-Q 季報,以及向美國證券交易委員會(SEC)提交的其他報告中所討論的因素。
Any forward-looking statements represent our views only as of today, November 10, 2026. A replay of the call will be available on our website following its completion.
任何前瞻性陳述僅代表我們截至今日(2026 年 11 月 10 日)的觀點。電話會議結束後,重播將可在我們的網站上收聽。
With that, I'll turn the call over to Linda Marban, CEO.
接下來,我將把電話會議交給執行長 Linda Marban。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Good afternoon, everyone, and thank you for joining us. Let me remind you that as Duchenne muscular dystrophy progresses, boys and young men lose the use of their arms and hands, the ability to feed themselves, use a phone or computer, or handle the everyday tasks that keep them independent. The loss of independence is what Deramiocel is designed to slow, and is the focus of the refined indication now under FDA review. This quarter, we took important steps to strengthen that case, and I will walk you through them today.
各位下午好,感謝各位加入我們。我想提醒各位,隨著杜興氏肌肉失養症(Duchenne muscular dystrophy, DMD)惡化,男孩與年輕男性會逐漸失去手臂與手的使用能力,無法自行進食、使用手機或電腦,或處理讓他們保持獨立的日常事務。Deramiocel 的設計目的在於減緩這種獨立能力的喪失,而這也是目前在 FDA 審查中的精煉適應症之重點。本季我們採取了重要步驟以強化這項主張,今天我將帶各位逐一說明。
Our BLA for Deramiocel is in the final stages of FDA review. Out of respect for that process, I will keep my comments on our interactions with the agency to what is already public. Today, I will cover four areas: our regulatory status, our data, our commercial and manufacturing readiness, and our dispute with NS Pharma. And then we will close with a brief pipeline update before handing it off to AJ.
我們針對 Deramiocel 的 BLA 目前正處於 FDA 審查的最後階段。出於對該審查流程的尊重,我將把對我們與主管機關互動的評論限於已公開的資訊。今天我將涵蓋四個面向:我們的法規狀態、我們的數據、我們的商業化與製造準備情況,以及我們與 NS Pharma 的爭議。之後在交棒給 AJ 之前,我們會以簡短的研發管線更新作結。
First, let me talk about our regulatory status. Following the advisory committee meeting, we held discussions with the agency. FDA then agreed to review additional data in a major amendment to our BLA and extended the PDUFA target action date to November 22, 2026.
首先,我先談我們的法規狀態。在諮詢委員會會議之後,我們與主管機關進行了討論。FDA 隨後同意在我們的 BLA 重大修訂中審查額外數據,並將 PDUFA 目標行動日期延後至 2026 年 11 月 22 日。
In August, we submitted that amendment, which included approximately 30,000 pages of documents, reports, tables, listings, and files, and datasets. It included the 24-month open-label extension data from HOPE-3, along with additional sensitivity and robustness analyses. It also included an integrated summary of efficacy, combining HOPE-2 and HOPE-3 efficacy data.
8 月,我們提交了該修訂案,其中包含約 30,000 頁的文件、報告、表格、清單與檔案,以及資料集。內容包括 HOPE-3 的 24 個月開放標籤延伸(open-label extension)數據,以及額外的敏感度與穩健性分析。同時也包含一份整合的療效摘要,合併 HOPE-2 與 HOPE-3 的療效數據。
Taken together, we believe these data support the refined indication, the treatment of upper limb impairment in patients with DMD ages greater than nine years old, the population studied in HOPE-3, and the focus of its primary endpoint. At this time, all requested information has been submitted to FDA, and the review remains ongoing.
綜合而言,我們相信這些數據支持精煉適應症:治療 9 歲以上 DMD 患者的上肢功能受損;這正是 HOPE-3 所研究的人群,也是其主要終點的重點。截至目前,所有 FDA 要求的資訊均已提交,審查仍在進行中。
Now let me turn to our data. I would like to walk you through the full dataset in chronological order, the one-year randomized results, the two-year data we provided in the amendments, and what we believe the totality of the evidence tells us.
接下來我談我們的數據。我想依時間順序帶各位回顧完整資料集:一年的隨機分派結果、我們在修訂案中提供的兩年數據,以及我們認為整體證據所傳達的訊息。
The full HOPE-3 results, published in The Lancet this past July following extensive peer review, showed that the trial met its primary efficacy endpoint, a statistically significant slowing of upper limb disease progression as measured by the Performance of the Upper Limb 2.0, a validated measure of shoulder, arm, and hand function, with a P-value of 0.029. The trial was designed to detect a difference of approximately 1 point, a threshold that physicians who treat Duchenne and the FDA have described as clinically meaningful, and that's what we saw. The absolute difference between the Deramiocel and placebo groups was 1.1 points, a result that was both clinically meaningful and statistically significant.
HOPE-3 的完整結果在今年 7 月經過嚴格同儕審查後發表於《The Lancet》,顯示該試驗達成其主要療效終點:以 Performance of the Upper Limb 2.0(上肢功能表現量表 2.0)衡量,上肢疾病進展出現具統計顯著意義的減緩;該量表為經驗證的肩部、手臂與手部功能衡量指標,P 值為 0.029。該試驗設計用以偵測約 1 分的差異,這一門檻已被治療杜興氏的醫師與 FDA 描述為具臨床意義,而我們確實觀察到此結果。Deramiocel 組與安慰劑組之間的絕對差異為 1.1 分,該結果同時具臨床意義且具統計顯著性。
For a boy who can no longer walk, a single point on this scale can mean keeping the ability to feed himself, bring a hand to his mouth, or operate his wheelchair or telephone. Other secondary endpoints measuring upper limb function, such as the Mid-Level Performance of the Upper Limb and the Duchenne Video Assessment, told the same story.
對於一位已無法行走的男孩而言,這個量表上的 1 分可能意味著仍能保有自行進食、把手抬到嘴邊,或操作輪椅或電話的能力。其他衡量上肢功能的次要終點,例如 Mid-Level Performance of the Upper Limb 與 Duchenne Video Assessment,也呈現相同的結論。
HOPE-3 also evaluated cardiac outcomes. This past weekend, Dr. Jonathan Soslow of Vanderbilt University presented the HOPE-3 cardiac data at the American Heart Association's Scientific Sessions in Chicago. As we announced yesterday, the abstract received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. This is a significant achievement, and to our knowledge, a first for research in DMD cardiomyopathy.
HOPE-3 也評估了心臟相關結果。上週末,范德堡大學的 Jonathan Soslow 醫師在芝加哥舉行的美國心臟協會(American Heart Association)科學年會上發表 HOPE-3 的心臟數據。如同我們昨日宣布,該摘要獲得美國心臟協會的小兒心臟科傑出研究獎(Outstanding Research Award in Pediatric Cardiology)。這是一項重要成就,據我們所知,這也是 DMD 心肌病研究的首次。
As a reminder, and the slides are available on our website, compared with placebo, Deramiocel slowed the progression of heart muscle scarring as measured by LGE on cardiac MRI. Across all patients, the difference in ejection fraction did not reach statistical significance. However, in patients with existing cardiomyopathy, ejection fraction improved by approximately 2.8 percentage points relative to placebo.
提醒各位(投影片已公布於我們網站),與安慰劑相比,Deramiocel 可減緩以心臟 MRI 的 LGE 所測得之心肌纖維化(疤痕)進展。在所有患者中,射出分率的差異未達統計顯著性。然而,在既有心肌病的患者中,相較於安慰劑,射出分率約提升 2.8 個百分點。
Of note, patients with preexisting cardiomyopathy were a prespecified subgroup in the HOPE-3 clinical trial. The findings were also supported by a post hoc comparison to the natural history dataset collected by the Duchenne Muscular Dystrophy Cardiac Care Consortium and led by Dr. Soslow.
值得注意的是,既有心肌病患者在 HOPE-3 臨床試驗中屬於預先指定(prespecified)的亞組。這些發現亦獲得事後(post hoc)與自然病程資料集之比較所支持;該資料集由杜興氏肌肉失養症心臟照護聯盟(Duchenne Muscular Dystrophy Cardiac Care Consortium)收集,並由 Soslow 醫師主導。
Now, let me discuss the open-label extension data from year two of our HOPE-3 clinical trial. In October, we presented the 24-month HOPE-3 data at the World Muscle Society Congress in Hiroshima, Japan. In the second year, all patients were eligible to be rolled over into an open-label study, and 82 patients received Deramiocel for a full year, which led us to ask a simple question: what happens when patients on placebo start treatment?
現在,我來談我們 HOPE-3 臨床試驗第二年的開放標籤延伸數據。10 月,我們在日本廣島舉行的世界肌肉學會(World Muscle Society)大會上發表了 HOPE-3 的 24 個月數據。在第二年,所有患者皆可轉入開放標籤研究,其中有 82 位患者接受 Deramiocel 治療滿一年,這讓我們提出一個簡單的問題:當原本使用安慰劑的患者開始接受治療時,會發生什麼?
In their first year, patients on placebo lost about two points on the Performance of the Upper Limb, which is consistent with natural history. However, when those same patients started on Deramiocel, their decline in their second year slowed to about 0.5 point, a difference of 1.56 points, comparable to a clinically meaningful change observed in the randomized phase of HOPE-3. This also represents a 76% slowing of disease progression from year one on placebo to year two on Deramiocel.
在第一年,安慰劑組患者在 Performance of the Upper Limb 上約下降 2 分,這與自然病程一致。然而,當同一批患者開始使用 Deramiocel 後,他們在第二年的下降幅度放緩至約 0.5 分,差異為 1.56 分,與 HOPE-3 隨機分派階段所觀察到的具臨床意義變化相當。這也代表從第一年使用安慰劑到第二年使用 Deramiocel,疾病進展速度減緩了 76%。
In other words, disease progression slowed substantially once patients initiated Deramiocel treatment. Importantly, patients who started on Deramiocel in the randomized portion of the trial lost less than 1 point in year one and maintained a similarly slow rate of decline in year two, supporting the durability of the treatment effect.
換言之,一旦患者開始接受 Deramiocel 治療,疾病進展便顯著放緩。重要的是,在試驗隨機分派部分一開始就使用 Deramiocel 的患者,第一年下降不到 1 分,第二年也維持類似的緩慢下降速率,支持治療效果的持久性。
We also compared both groups at two years to what natural history would predict for a similar patient population using two well-known datasets. By month 24, both groups had declined less than predicted, 3.4 points against the predicted 5.9 points in the group treated from the start, and 3.8 points against 5.4 points in the group that started on placebo. The slide depicting this data is available on our website in the HOPE-3 OLE presentation from the World Muscle Society. Most importantly, the placebo group had a similar slope of decline to the natural history group until they went on Deramiocel, and then the difference was striking.
我們也使用兩個知名資料集,將兩組患者在兩年時的結果與相似患者族群的自然病程預測進行比較。至第 24 個月時,兩組的下降幅度皆低於預測:自一開始即接受治療的組別下降 3.4 分(預測為 5.9 分);先使用安慰劑後開始治療的組別下降 3.8 分(預測為 5.4 分)。呈現此數據的投影片可在我們網站上、世界肌肉學會的 HOPE-3 OLE 簡報中取得。最重要的是,安慰劑組在改用 Deramiocel 之前,其下降斜率與自然病程組相近;一旦改用 Deramiocel,差異便十分明顯。
While these open-label results are descriptive, they are consistent with our randomized data and support the potential of Deramiocel to slow Duchenne muscular dystrophy progression. FDA has increasingly recognized the role of real-world evidence and has recently approved several products where natural history data played an important role in establishing efficacy.
雖然這些開放標籤結果屬於描述性資料,但與我們的隨機化數據一致,並支持 Deramiocel 具有減緩杜興氏肌肉失養症(Duchenne muscular dystrophy, DMD)病程進展的潛力。FDA 日益認可真實世界證據(real-world evidence)的角色,且近期已核准數項產品,其中自然病程(natural history)數據在建立療效方面扮演了重要角色。
That brings me to the full body of evidence and to its strengths, because we know the advisory committee left many people with questions. The concern we heard most was fragility, the worry that a result might depend on a few patients or a single analysis choice. So we put our data to the test, and we shared that work with FDA in terms of these robustness analyses.
這就帶到完整的證據體系及其優勢,因為我們知道諮詢委員會讓許多人留下疑問。我們聽到最多的疑慮是結果的脆弱性(fragility),擔心結果可能取決於少數幾位病患或單一分析選擇。因此我們對數據進行壓力測試,並就這些穩健性(robustness)分析與 FDA 分享了相關工作。
The answer was clear. The size and direction of the benefit held up across the analyses. For instance, the robustness analyses submitted to FDA ran more than 900 different re-analyses using the HOPE-3 data to answer one question: how fragile were the results? The analyses addressed multiple questions raised by the FDA and the advisory committee, including how missing data is handled, which patients are included, and how progression is defined. If the results were fragile, the benefit would shrink or disappear.
答案很清楚。在各項分析中,療效的幅度與方向都能成立。例如,提交給 FDA 的穩健性分析使用 HOPE-3 數據進行了超過 900 種不同的重新分析,只為回答一個問題:結果有多脆弱?這些分析回應了 FDA 與諮詢委員會提出的多項問題,包括如何處理缺失數據、納入哪些病患,以及如何定義疾病進展。如果結果是脆弱的,療效就會縮小或消失。
However, in the large majority of these analyses, the result was at or near statistical significance with a P-value of P equals or less than 0.05. Across the analyses, the estimated benefit stayed centered on about 1 point on PUL 2.0, a level that is clinically meaningful, and every analysis favored Deramiocel. Not one favored placebo.
然而,在絕大多數分析中,結果達到或接近統計顯著性,P 值為 P 等於或小於 0.05。於各項分析中,估計療效仍集中在 PUL 2.0 約 1 分左右,這在臨床上具有意義,而且每一項分析都支持 Deramiocel。沒有任何一項支持安慰劑。
We also included an integrated summary of efficacy, or ISE, in the major amendment, which brings together data from HOPE-2 and HOPE-3. An ISE is generally included in BLA submissions. In the ISE, we analyzed the data from our two placebo-controlled trials, HOPE-2 and HOPE-3, which used the same dosing and the same assessments.
我們也在重大修訂(major amendment)中納入整合療效摘要(integrated summary of efficacy, ISE),彙整 HOPE-2 與 HOPE-3 的數據。ISE 通常會納入 BLA 申請文件中。在 ISE 中,我們分析了兩項安慰劑對照試驗 HOPE-2 與 HOPE-3 的數據,兩者使用相同的給藥方案與相同的評估方式。
With more patients, the picture became clearer. At 12 months, measurement of skeletal muscle function using the same PUL measures showed that those patients on placebo lost about 2 points of upper limb function, while the patients on Deramiocel lost less than 1 point, a combined difference of 1.29 points and a P-value of 0.0087. All eight sensitivity analyses pointed the same way. On the cardiac side, the integrated analysis of ejection fraction across both trials favored Deramiocel by about 2.2 percentage points, and the direction held across the sensitivity analyses.
隨著病患數增加,整體圖像更為清晰。在 12 個月時,使用相同的 PUL 指標衡量骨骼肌功能顯示:安慰劑組病患上肢功能約下降 2 分,而 Deramiocel 組病患下降不到 1 分,合併差異為 1.29 分,P 值為 0.0087。八項敏感性分析皆指向相同方向。在心臟方面,跨兩項試驗的射出分率(ejection fraction)整合分析顯示 Deramiocel 約優於 2.2 個百分點,且在敏感性分析中方向一致。
Put simply, the data tell a consistent story. One year, two years, two randomized trials, and a decade of clinical experience all points in the same direction. We do not believe that this is a case that rests solely on unmet medical need, secondary endpoints, or regulatory flexibility.
簡而言之,數據呈現一致的故事。一年、兩年、兩項隨機試驗,以及十年的臨床經驗,都指向同一個方向。我們不認為這是一個僅僅建立在未被滿足的醫療需求、次要終點或監管彈性之上的案例。
HOPE-3 met its primary efficacy endpoint. The long-term data show the same trajectory. The natural history comparison suggests Deramiocel slows the progression of the disease. Safety continues to be a core strength of this program. Across three clinical trials, more than 125 patients with DMD have received over 1,300 infusions of Deramiocel. More than 80 patients continue in our open-label extension studies, some for more than five years, and Deramiocel has been generally well-tolerated throughout.
HOPE-3 達成其主要療效終點。長期數據顯示相同的趨勢軌跡。自然病程比較顯示 Deramiocel 可減緩疾病進展。安全性仍是本計畫的核心優勢。在三項臨床試驗中,超過 125 名 DMD 病患已接受超過 1,300 次 Deramiocel 輸注。超過 80 名病患仍持續參與我們的開放標籤延伸研究,其中部分已超過五年,且整體而言 Deramiocel 在全程均具有良好耐受性。
Others have reached similar conclusions. The HOPE-3 results were published in The Lancet. The cardiac data received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The data were presented at the World Muscle Society, and at the advisory committee meeting, 26 speakers in the open public hearing urged that Deramiocel be made available to people living with DMD.
其他人也得出了類似結論。HOPE-3 結果已發表於《刺胳針》(The Lancet)。心臟數據獲得美國心臟協會(American Heart Association)兒科心臟病學傑出研究獎(Outstanding Research Award)。相關數據亦於世界肌肉學會(World Muscle Society)發表;在諮詢委員會會議的公開聽證中,有 26 位發言者呼籲應讓 Deramiocel 提供給 DMD 患者使用。
Finally, as many of you may have seen, Dr. Craig McDonald and 27 other Duchenne clinicians and researchers, including the HOPE-3 investigators, sent a letter to FDA, which they have since made public. In it, they explain why they believe FDA should approve Deramiocel based on the strength of the data, not just the unmet medical need.
最後,如各位可能已看到的,Craig McDonald 醫師與另外 27 位杜興氏領域臨床醫師與研究人員(包括 HOPE-3 研究者)致函 FDA,並已將該信公開。信中說明他們為何認為 FDA 應基於數據的強度核准 Deramiocel,而不僅僅是基於未被滿足的醫療需求。
Now let me turn to our commercial readiness and manufacturing. Approximately 15,000 people in the US are living with DMD, and we estimate that roughly two-thirds are ages nine and older, the population our proposed refined indication would address. Most boys lose the ability to walk by their early teens, and from then on, their arms and hands are what keep them independent. Yet there is no therapy approved specifically to preserve upper limb function. HOPE-3 was designed for exactly this group, including those who are primarily non-ambulant, patients who have historically been underrepresented in Duchenne clinical trials.
接下來我談談我們的商業化準備與製造。美國約有 15,000 人罹患 DMD,我們估計其中約三分之二為 9 歲及以上,這正是我們擬議之精煉適應症(refined indication)所涵蓋的人群。多數男孩在十幾歲初期就會失去行走能力,之後手臂與雙手成為維持其獨立性的關鍵。然而,目前尚無任何療法獲准專門用於維持上肢功能。HOPE-3 正是為這一族群而設計,包括以非行走(non-ambulant)為主的患者;這些患者在杜興氏臨床試驗中歷來代表性不足。
We are continuing our commercial readiness activities in a disciplined way, pacing spend as the regulatory timeline evolves. Launch planning is underway across all critical functions, including distribution, patient support, market access, medical affairs, and physician education. Payer discussions have begun, and we will share more at the appropriate time.
我們正以嚴謹有紀律的方式持續推進商業化準備工作,並隨監管時程的演進調整支出節奏。上市規劃已在所有關鍵職能展開,包括配送、病患支持、市場准入、醫藥事務與醫師教育。與支付方(payer)的討論已開始,我們將在適當時機分享更多資訊。
In terms of manufacturing, our San Diego GMP facility is up and running and ready to supply an initial launch if Deramiocel is approved. Build-out of the second floor, our facility is progressing, with validation targeted for the first half of 2027. Once complete, we expect this facility to support 2,000 to 2,500 patients, or up to 10,000 doses per year operating at full capacity, giving us room to grow based on demand.
在製造方面,我們位於聖地牙哥的 GMP 廠已啟用運轉,若 Deramiocel 獲准,已準備好支援初期上市供應。我們設施二樓的擴建工程正持續推進,目標於 2027 年上半年完成驗證(validation)。完成後,我們預期該設施可支援 2,000 至 2,500 名病患,或在滿載產能下每年最多 10,000 劑量,讓我們能依需求成長而擴充。
Now turning to our dispute with NS Pharma. We continue to pursue our contractual dispute with Nippon Shinyaku and NS Pharma regarding the Deramiocel distribution agreement. As we have previously shared, we withdrew our motion for a preliminary injunction without prejudice to resolve the dispute in arbitration following the FDA's decision, and we expect the arbitration hearing to commence in mid-2027. Our position on the underlying dispute has not changed, and we will share more updates on this as they become available.
接著談我們與 NS Pharma 的爭議。我們持續就 Deramiocel 配送協議,與 Nippon Shinyaku 及 NS Pharma 的合約爭議進行追訴。如先前所分享,我們已撤回初步禁制令(preliminary injunction)動議且不影響權利(without prejudice),以便在 FDA 作出決定後透過仲裁解決爭議;我們預期仲裁聽證將於 2027 年年中開始。我們對於爭議核心事項的立場並未改變,並將在有更多進展時提供更新。
Finally, our pipeline and organization. To keep our resources focused on Deramiocel, we have moderated the pace of pipeline work not directly tied to it until we have further regulatory clarity. As part of that same discipline, we reduced our workforce by approximately 10% in the third quarter to align our organization with our near-term priorities. These were not easy decisions, and we are grateful to the colleagues who contributed to Capricor and have gone in different directions now.
最後,談我們的產品管線與組織。為使資源聚焦於 Deramiocel,在取得更明確的監管方向之前,我們已放緩與其不直接相關的管線工作進度。秉持同樣的紀律,我們在第三季將人力縮減約 10%,以使組織與近期優先事項一致。這些決定並不容易,我們也感謝曾為 Capricor 做出貢獻、如今已走向不同道路的同仁。
Outside the US, we have initiated regulatory engagement in Europe and Japan. Evaluating Deramiocel in younger boys with DMD and Becker muscular dystrophy remain an area of focus, with next steps to be informed by the outcome of the US review.
在美國以外,我們已在歐洲與日本啟動監管互動。在較年幼的 DMD 男孩以及貝克型肌肉失養症(Becker muscular dystrophy)患者中評估 Deramiocel 仍是重點領域,後續步驟將依美國審查結果而定。
We look forward to sharing more about our longer-term pipeline vision as the Deramiocel review progresses, and I will now hand it over to AJ to walk through the financials.
隨著 Deramiocel 的審查持續推進,我們期待分享更多關於我們較長期產品線願景的內容;接下來我把時間交給 AJ,請他帶大家回顧財務狀況。
Anthony Bergmann - Chief Financial Officer
Anthony Bergmann - Chief Financial Officer
Thank you, Linda. As of September 30, 2026, Capricor's cash, cash equivalents, restricted cash, and marketable securities totaled approximately $198.5 million. No shares were sold under our ATM program this year, and there has been no revenue recognized for the third quarter of 2026 or '25.
謝謝你,Linda。截至 2026 年 9 月 30 日,Capricor 的現金、約當現金、受限制現金及有價證券合計約為 1.985 億美元。今年我們未透過 ATM 計畫出售任何股份,且 2026 年或 2025 年第三季均未認列任何營收。
Turning to operating expenses for the third quarter of 2026 were approximately $44.7 million, compared to approximately $26.3 million for the third quarter of 2025. The increase was primarily driven by pre-commercial activities and manufacturing scale-up.
第三季 2026 年的營業費用約為 4,470 萬美元,相較於 2025 年第三季約 2,630 萬美元。增加主要來自商業化前活動以及製造產能擴增。
Net loss for the third quarter of 2026 was approximately $42.7 million, or $0.73 per share, compared to a net loss of approximately $24.6 million, or $0.54 per share, for the third quarter of 2025. For the nine months ended September 30, 2026, our net loss was approximately $117.3 million, compared to approximately $74.9 million for the same period of 2025.
2026 年第三季淨損約為 4,270 萬美元,或每股 0.73 美元;相較之下,2025 年第三季淨損約為 2,460 萬美元,或每股 0.54 美元。截至 2026 年 9 月 30 日止的九個月期間,我們的淨損約為 1.173 億美元,相較於 2025 年同期約 7,490 萬美元。
We continue, as Linda mentioned, to pace commercial spending to the regulatory timeline, and our workforce reduction further aligns our cost structure with our priorities. Based on our current operating plan, we believe our existing cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months.
如 Linda 所提,我們持續依照法規時程來調整商業支出節奏,而我們的人力縮減也進一步使成本結構與優先事項更一致。根據我們目前的營運計畫,我們相信現有的現金、約當現金及有價證券足以支應至少未來 12 個月的營運。
And with that, we will now open up the line for Q&A.
接下來,我們將開放 Q&A。
Operator
Operator
Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. (Operator Instructions)
謝謝。各位女士、先生,我們現在開始問答環節。(接線員指示)
Leland Gershell, Oppenheimer.
Leland Gershell,Oppenheimer。
Leland Gershell - Analyst
Leland Gershell - Analyst
Great. Thank you very much for the update and taking our questions, and congrats on receiving the AHA award. Just actually a question on the cardiomyopathy data. Wondering, Linda, even though you didn't show significance on the overall population as evaluated for LVEF on the secondary, but did on the cardiomyopathy subgroup, just wondering if from the data that you have to date comprehensively, if you can offer perspective on how long Deramiocel could delay the onset of clinical cardiomyopathy in patients who don't yet have it, should they begin treatment perhaps before they actually have clinical cardiomyopathy? Thanks.
太好了。非常感謝你們的最新進展並回答我們的問題,也恭喜獲得 AHA 獎項。我想問一個關於心肌病變數據的問題。Linda,我想了解的是,雖然你們在整體族群、以 LVEF 作為次要終點的評估上沒有顯著性,但在心肌病變亞組卻有顯著性;想請教就目前你們掌握的完整數據而言,能否分享 Deramiocel 對於尚未出現臨床心肌病變的患者,若在真正出現臨床心肌病變之前就開始治療,可能可以延後臨床心肌病變發生多久的看法?謝謝。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah. Thanks, Leland. That's raised some really important points. So I'd like to highlight that in the intention-to-treat population of the HOPE-3 study, which was not designed specifically to evaluate cardiomyopathy, therefore inclusion/exclusion criteria were not designed around cardiomyopathy. Approximately one-third of the patients were healthier, had ejection fractions well within the normal range, and you can't make a healthy heart healthier, so to speak.
是的。謝謝你,Leland。你提出了一些非常重要的觀點。我想強調的是,在 HOPE-3 研究的意向治療(ITT)族群中,該研究並非專為評估心肌病變而設計,因此納入/排除標準也不是以心肌病變為核心來制定。約三分之一的患者較為健康,射出分率在正常範圍內;某種程度上,你無法讓一顆健康的心變得「更健康」。
So, in fact, the fact that we were nearing significance in the full ITT population portended the value of the therapeutic in those with cardiomyopathy. And those with cardiomyopathy, unequivocally, which was two-thirds of the population in the HOPE-3 study, unequivocally, we saw a clinical and statistically significant benefit. So, that's very important to note that in the patients with cardiomyopathy, Deramiocel definitely shows a benefit and is similar to the benefit already shown in the HOPE-2 clinical trial.
因此,事實上,我們在整體 ITT 族群中接近顯著性,反而預示了該療法在心肌病變患者中的價值。而在心肌病變患者中——毫無疑問地——也就是 HOPE-3 研究中占三分之二的族群,我們觀察到具臨床意義且具統計顯著性的效益。所以,非常重要的一點是:在心肌病變患者中,Deramiocel 確實展現效益,且與先前在 HOPE-2 臨床試驗中已顯示的效益相近。
In terms of your very important question, which is, can we delay the progression of cardiomyopathy long-term and prevent the development of long-term functional consequences? This will require longer-term evaluation of these patients in terms of ejection fraction.
至於你提出的這個非常重要的問題——也就是我們是否能長期延緩心肌病變的進展並預防長期功能性後果的發生——這需要對這些患者進行更長期的射出分率追蹤評估。
What we know from our clinical leaders in cardiology, including Jonathan Soslow, who presented the data, is that we had a reduction in the amount of scar in the heart, and that was evident from pretty early on. And what we know is that kids get scarred pretty young. So if we can get Deramiocel to their hearts early, prevent the development of the scar, it's likely that it will delay the progression of the onset or continuation of the cardiomyopathy. And we look forward to having that opportunity, both commercially and clinically, to continue that program of understanding the cardiomyopathy associated with Duchenne.
我們從心臟科的臨床領導者(包括發表數據的 Jonathan Soslow)那裡得知,我們觀察到心臟疤痕量的降低,而且這在相當早期就已顯現。我們也知道,孩子在很小的年紀就會產生疤痕。因此,如果我們能及早讓 Deramiocel 作用於他們的心臟、預防疤痕形成,很可能就能延後心肌病變的發生或其持續進展。我們也期待在商業化與臨床上都有機會持續推進該計畫,以加深對杜興氏肌營養不良症相關心肌病變的理解。
Operator
Operator
Ted Tenthoff, Piper Sandler.
Ted Tenthoff,Piper Sandler。
Edward Tenthoff - Analyst
Edward Tenthoff - Analyst
Great. Thank you so much for taking the questions, and fingers crossed coming up with the PDUFA date. I really hope the FDA sees the value that everybody recognizes in this drug. I know you went through some details with respect to launch prep on the positive outcome. What can you tell us in terms of manufacturing supply now and kind of how that will expand going forward? Thank you.
太好了。非常感謝你們回答問題,也希望 PDUFA 日期能順利出爐。我真的希望 FDA 能看到大家都認同這款藥物的價值。我知道你們已就正面結果下的上市準備分享了一些細節。就目前的製造供應,以及未來將如何擴增產能,你們可以跟我們說些什麼?謝謝。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah. Thanks, Ted. Obviously, it's been really one of the important aspects of our clinical development program was to have manufacturing come along behind, and the development of our GMP facility here in San Diego was critical in that it passed PLI inspection. And the first floor clean room is ready to go to be able to meet the needs of 250 patients per year or numbers of doses that are equivalent to that, around 1,000 doses per year; which is important because remember, patients typically get a dose every quarter, so you can actually have a lot more patients that are treated without hitting that year mark.
是的。謝謝你,Ted。顯然,我們臨床開發計畫中非常重要的一環,就是讓製造端能夠同步跟上;而我們在聖地牙哥的 GMP 廠房建置至關重要,因為它已通過 PLI 稽核。一樓無塵室已準備就緒,可滿足每年 250 名患者的需求,或相當於該需求的劑量數,約每年 1,000 劑;這點很重要,因為請記得患者通常每季給藥一次,因此在不觸及年度上限的情況下,實際可治療的患者數可以更多。
Our second-floor facility is pretty much built out. We're going to be finishing clean rooms sort of in sequential order as demand implies. And that facility, as I stated, can meet the needs of about 2,500 patients annually. So we don't anticipate that supply will be a problem either in early stages of launch or as we continue commercial development.
我們二樓的設施幾乎已完成建置。我們將依需求所示,按序完成各無塵室的建置。如我所述,該設施每年可滿足約 2,500 名患者的需求。因此,無論是在上市初期或我們持續推進商業化開發的過程中,我們都不預期供應會成為問題。
If we are lucky enough to get approval in the US, we're poised to continue the expansion of our manufacturing footprint into a new facility in San Diego, which we've already tentatively agreed to occupy and build out should the need prevail.
如果我們有幸在美國獲得核准,我們也已準備好將製造版圖擴展至聖地牙哥的一處新設施;若需求確實存在,我們已初步同意進駐並進行建置。
Edward Tenthoff - Analyst
Edward Tenthoff - Analyst
Great. Thank you very much. Good luck.
太好了。非常感謝。祝你們好運。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thank you, Ted. Take good care.
謝謝你,Ted。請多保重。
Operator
Operator
Kristen Kluska, Cantor Fitzgerald.
Kristen Kluska,Cantor Fitzgerald。
Unidentified Participant
Unidentified Participant
Hi. This is [Ian] on Kristen's line. Thank you for taking our questions here. With the arbitration hearing expected to begin mid-2027 next year, I'm just wondering how you see this potentially impacting bringing Deramiocel to market if approved later this month.
嗨,我是 Kristen 線上的 [Ian]。謝謝你們在這裡回答我們的問題。由於仲裁聽證預計將於明年 2027 年年中開始,我想請教你們認為這可能會如何影響 Deramiocel(若在本月稍晚獲核准)推向市場的進程?
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
So regardless of how the dispute is resolved, we are prepared. Our San Diego facility is operational, as I just mentioned a moment. We are building out patient support, market access, and med affairs. We'll share more on our specific commercialization plans following the FDA's decision.
無論爭議最終如何解決,我們都已做好準備。正如我剛才提到的,我們在聖地牙哥的設施已可運作。我們正在建置患者支持、市場准入以及醫療事務。在 FDA 做出決定後,我們將分享更多具體的商業化計畫。
Obviously, if it's positive, commercialization will become our key focus, and then we will have updates to the street. We don't anticipate that the arbitration or its continuance or conduction will impact our ability to bring Deramiocel to patients, and that's going to be our goal. We want to take care of those boys and young men with DMD.
顯然,如果結果是正面的,商業化將成為我們的重點,之後我們也會向市場更新。我們不預期仲裁或其延續或進行會影響我們將 Deramiocel 帶給病患的能力,而這將是我們的目標。我們希望照顧那些罹患 DMD 的男孩與年輕男性。
Unidentified Participant
Unidentified Participant
Sounds good. Thanks for that, Linda. Just one more from us. With the July inspection, which you indicated that you have already submitted a response, I'm just wondering if the FDA could proceed with an approval before formally responding. I'm just wondering your thoughts on this.
聽起來不錯。謝謝你,Linda。我們這邊再一個問題。關於 7 月的查廠,你提到你們已經提交回覆,我想請問 FDA 是否可能在正式回覆之前就先行核准。想聽聽你的看法。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah. That's in the hands of FDA. I don't know exactly how they manage it. We have had no further follow-up or questions related to that inspection.
是的。那要看 FDA。 我不太清楚他們具體怎麼處理。我們沒有收到任何與那次查廠相關的後續追蹤或問題。
We sent in all the requisite documents, and they closed out the actual inspection itself. So in terms of how FDA will manage that information in terms of the timelines of approval is really in the hands of FDA.
我們已提交所有必要文件,而他們也結案了那次實際的查廠。因此,FDA 將如何在核准時程上運用這些資訊,確實完全取決於 FDA。
Unidentified Participant
Unidentified Participant
All right. Thank you, Linda. If I could just sneak in one more, I'm sorry. If I recall correctly, the FDA previously inspected the San Diego facility in 2025. I'm just wondering if you anticipate any additional inspections ahead of the PDUFA date here?
了解。謝謝你,Linda。不好意思我再插問一個。如果我沒記錯,FDA 之前在 2025 年已查過聖地牙哥的廠。我想請問在這裡距離 PDUFA 日期之前,你們是否預期還會有任何額外查廠?
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Well, the PDUFA date is in 12 days, so they better hurry up if they are going to -- no, no. I'm being a little silly. No, we do not anticipate any more. I think what we've heard is that they've conducted the inspections that they need to. They have the data that they seem to need, and we haven't heard anything.
嗯,PDUFA 日期只剩 12 天了,所以如果他們要——那就得趕快了——不不。我只是開個玩笑。不,我們不預期還會有更多查廠。我們聽到的訊息是,他們已完成所需的查廠。他們似乎也已取得所需的資料,而我們沒有再聽到任何消息。
Obviously, we'll update the street should anything become clear that they need to do any more. But right now, we're thinking we're done.
當然,如果有任何跡象顯示他們需要再做更多,我們會向市場更新。但目前我們認為已經完成了。
Unidentified Participant
Unidentified Participant
Sounds good. Thank you, Linda, and we're rooting for you.
聽起來很好。謝謝你,Linda,我們也為你們加油。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thank you. Tell Kristen we said hi.
謝謝。也請跟 Kristen 說我們問候她。
Operator
Operator
Madison El-Saadi, B. Riley Securities.
Madison El-Saadi,B. Riley Securities。
Madison El-Saadi - Analyst
Madison El-Saadi - Analyst
Hey, guys. Thank you for taking our question. One from us. Would you expect any of the cardiomyopathy subgroup data, the LGE results, to appear anywhere in a potential label, even though the focus now is on upper limb? Or do you think this really even matters in terms of the potential launch?
嗨,各位。謝謝讓我們提問。我們這邊一個問題。即使目前重點放在上肢功能,你們是否預期任何心肌病變亞組資料(LGE 結果)會出現在潛在的標籤上?或者你認為這對於潛在上市推進其實並不重要?
Maybe manufacturing is the greater constraint on scaling. I appreciate any color there. Thanks.
也許製造端才是擴產放量的更大限制。希望你能提供一些看法。謝謝。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thanks, Madison. Yeah, so we're not disclosing the label information at this point. What I can tell you is I'm very bullish, personally and professionally, on the cardiomyopathy data. And whether it's in the label now or will be a future of label expansion is something that we'll update people on later. But that data's good, and the patients definitely deserve it.
謝謝你,Madison。是的,我們目前不會揭露標籤內容。我能告訴你的是,無論從個人或專業角度,我對心肌病變資料都非常看好。至於它是否會在現在的標籤中,或是未來作為標籤擴增的一部分,我們之後會再向大家更新。但那份資料很不錯,病患也確實值得擁有。
Madison El-Saadi - Analyst
Madison El-Saadi - Analyst
Understood. Thanks for taking our questions, and good luck.
了解。謝謝回答我們的問題,祝你們好運。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Of course. Thanks, Madison.
當然。謝謝你,Madison。
Operator
Operator
Rick Bienkowski, Ladenburg.
Rick Bienkowski,Ladenburg。
Rick Bienkowski - Equity Analyst
Rick Bienkowski - Equity Analyst
Hey, good afternoon, and thanks for taking the question. The press release mentioned the list of preparations that were being made for the commercial launch, including distribution, patient support, et cetera. It seemed like it was a pretty comprehensive list for launching a drug solo.
嗨,午安,謝謝讓我提問。新聞稿提到為商業上市所做的一系列準備,包括配送、病患支持等。看起來對於單獨推出一款藥物而言,這份清單相當完整。
So my question is, once we get to the other side of arbitration, what do you see as the role of NS Pharma here? And could any of these responsibilities eventually fall on NS?
所以我的問題是,一旦仲裁告一段落,你認為 NS Pharma 在這裡會扮演什麼角色?而這些職責是否有可能最終由 NS 承擔?
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah, thanks for the question. Right now, because the dispute is ongoing and the agreement is written by our interpretation of our lawyers as non-transactable, we're going independently in preparation for launch and commercialization of Deramiocel without the participation of NS Pharma at this point in any way.
是的,謝謝你的問題。目前由於爭議仍在進行中,且依我們律師的解讀,該協議屬於不可交易(non-transactable),因此我們正以獨立方式為 Deramiocel 的上市與商業化做準備,現階段不以任何形式讓 NS Pharma 參與。
Having said that, the arbitration panel obviously has important opportunities to direct how things go. And so in the future, if we work with NS, we will definitely disclose that and talk about that. But there's nothing better than being prepared, right? So we'd rather be prepared to go than unprepared.
話雖如此,仲裁小組顯然有重要的裁示空間來決定事情如何推進。因此未來若我們與 NS 合作,我們一定會揭露並說明。但準備充分總是更好,對吧?所以我們寧可準備好可以推進,也不要毫無準備。
Operator
Operator
(Operator Instructions)
(接線員指示)
Catherine Novack, Jones.
Catherine Novack,Jones。
Catherine Novack - Analyst
Catherine Novack - Analyst
Hi. Afternoon. Thanks for taking my question. Just curious, in light of AHA's response to the cardiac data from HOPE-3, can you give us a sense of what additional data they saw that maybe FDA didn't have access to when they wrote the briefing documents going to the AdCom?
嗨,午安。謝謝讓我提問。我想請教,鑑於 AHA 對 HOPE-3 心臟資料的回應,你能否讓我們了解他們看到了哪些額外資料,可能是 FDA 在撰寫提交給 AdCom 的簡報文件時尚未取得的?
What do you think the most notable outcome was from AHA's perspective? And then how many of the information requests that you got from FDA were related to anything cardiac? Thanks.
從 AHA 的角度來看,你認為最值得注意的結論是什麼?另外,FDA 向你們提出的資訊請求(IR)中,有多少是與心臟相關的?謝謝。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah. So thanks for that. In terms of AHA, I think there was a totality of the data that drove them. The observation that DMD cardiomyopathy is an important problem and seems to be addressed by Deramiocel. I think AHA also, and this is all supposition, obviously, but just based on my own experience with AHA, thought that the combination of scar data, LGE data, combined with function data was a really, really powerful tool. And so I think it was sort of all taken together.
好的,謝謝。就 AHA 而言,我認為是整體資料的綜合性促使他們做出那樣的判斷。他們觀察到 DMD 心肌病變是一個重要問題,而 Deramiocel 似乎能加以改善。我也認為 AHA——當然這都是推測——但以我對 AHA 的經驗來看,他們可能認為疤痕資料、LGE 資料再加上功能性資料的組合,是非常、非常有力的工具。所以我想他們是把所有資料放在一起綜合評估。
In terms of the additional data, I think what FDA now has, but was not part of the original review, is the open-label extension data compared to the natural history data, Jon Soslow's data set, and all the robustness analyses, which weren't really covered very much by the AHA data. But taken together, it's a much stronger data set showing long-term safety and efficacy.
至於額外資料,我認為 FDA 現在擁有、但原先審查時未納入的,是開放標籤延伸試驗(open-label extension)資料與自然病程資料(Jon Soslow 的資料集)的比較,以及所有穩健性分析;而這些在 AHA 的資料中並沒有被太多著墨。但合併起來看,這是一套更強的資料集,顯示長期安全性與療效。
In terms of IRs from FDA, which was the second part of your question, as I mentioned at the beginning, due to the sensitivity of the review process, we're really not disclosing what's communication between Capricor and FDA at this time.
至於 FDA 的 IR(也就是你問題的第二部分),如我一開始提到的,基於審查流程的敏感性,我們目前不會揭露 Capricor 與 FDA 之間的溝通內容。
Catherine Novack - Analyst
Catherine Novack - Analyst
Got it. Well, thanks, Linda.
了解。謝謝你,Linda。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thank you. Take good care.
謝謝。請多保重。
Operator
Operator
Joe Pantginis, H.C. Wainwright.
Joe Pantginis,H.C. Wainwright。
Joseph Pantginis - Analyst
Joseph Pantginis - Analyst
Hey, guys. Good afternoon. Thanks for taking the question and all the details today. So first, with regard to NS, what are the terms to potentially part ways here pending arbitration versus being able to just move on to potentially find someone else. Number one.
嗨,各位。午安。謝謝讓我提問,也謝謝今天提供的所有細節。首先,關於 NS,在仲裁結果出來之前,若要在此分道揚鑣的條件是什麼?相較之下,你們是否能直接往前走、可能去找其他合作方?這是第一點。
And then, obviously, you've made some thoughtful and required pipeline moves here, but are there any outstanding or ongoing ISTs with regard to the exosome programs that we can expect to hear some work or data from?
然後,很明顯你們在這裡已經做出一些深思熟慮且必要的管線調整,但就外泌體(exosome)專案而言,是否仍有任何尚未完成或正在進行的研究者發起試驗(IST),讓我們預期能聽到一些進展或數據?
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah. So, in terms of NS, we really are focusing now on independent launch and preparation for commercialization. That's going very smoothly, and we stand poised and ready to do an effective launch should we be lucky enough to achieve approval.
是的。所以,就 NS 而言,我們現在確實把重點放在獨立上市以及商業化準備上。進展非常順利,如果我們有幸獲得核准,我們已蓄勢待發,能夠有效地推動上市。
We're not looking, obviously, for another partner. I think that if we're lucky enough to achieve separation from NS completely, we'll do it on our own. It's a rare disease, and we're perfectly capable at this point in time of doing that, and I'm excited to have a good team in place to do so.
我們顯然不會再尋找另一個合作夥伴。我認為,如果我們有幸能夠完全與 NS 分離,我們會自己來做。這是一種罕見疾病,而以目前這個時間點,我們完全有能力做到這點,我也很期待能有一支優秀的團隊來執行。
In terms of exosome pipeline opportunities, we are working diligently in the background, as you know. We've talked about this for a long time. We've de-emphasized the pipeline to conserve cash over time and focus on Deramiocel.
就外泌體管線的機會而言,如你所知,我們一直在幕後努力推進。我們談這件事已經很久了。為了長期節省現金並聚焦 Deramiocel,我們已降低對管線的著墨。
We continue to do that, although we have some pretty exciting opportunities coming along in terms of the exosomes. We're successfully able to manufacture them to clinical and commercial scale now. We have GMP manufacturing of exosomes, and we have targeting and loading opportunities that we did not have before.
我們仍持續這麼做,不過在外泌體方面也有一些相當令人振奮的機會正在出現。我們現在已成功能將其製造到臨床與商業規模。我們具備外泌體的 GMP 製造能力,而且也有過去沒有的標靶化與載入(loading)機會。
And so all I can tell you is that we're still excited about them. We think that they are the future of drug delivery in many ways and look forward to sharing that as it moves forward.
所以我能告訴你的是,我們對它們仍然感到興奮。我們認為在許多方面,它們是藥物遞送的未來,也期待在推進過程中與大家分享。
Operator
Operator
Boobalan Pachaiyappan, ROTH Capital Partners.
Boobalan Pachaiyappan,ROTH Capital Partners。
Boobalan Pachaiyappan - Analyst
Boobalan Pachaiyappan - Analyst
Hi. Thanks for taking our questions. So I wanted to revisit the July AdCom, which voted on cardiomyopathy rather than the upper limb indication you're proposing now. So I'm just curious, whether during your interactions with the FDA, did they indicate that they can reach a decision using their existing vote or whoever they have advises it, or do you think there is a chance for a second AdCom focusing on?
嗨,謝謝回答我們的問題。我想回到 7 月的 AdCom,當時投票的是心肌病(cardiomyopathy),而不是你們現在提出的上肢適應症。所以我很好奇,在你們與 FDA 的互動中,他們是否表示可以依據既有的投票結果或由其顧問團隊來做出決定?或者你們認為是否有可能再召開第二次、聚焦於……的 AdCom?
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Well, they'd have 12 days to organize, conduct, and get the AdCom together if they stick with the current PDUFA dates. I don't think that's very likely. They use advisory committees in order to give them information or clarity in topics in which they don't feel they have enough information to render a decision. I think they got a lot of information from the AdCom.
嗯,如果他們維持目前的 PDUFA 日期,他們只有 12 天可以籌備、召開並把 AdCom 組織起來。我認為這不太可能。他們使用諮詢委員會是為了在某些他們覺得資訊不足以做出決定的議題上,獲得資訊或釐清。我認為他們從 AdCom 得到了很多資訊。
We tend to disagree with many of the ways that the AdCom was organized, including the question that was asked, which was probably the worst part of the entire decision process for the advisors and was evidenced by their comments made post-vote. No, I don't think that there'll be another AdCom within the next 12 days, but if there is, I suppose we'll be ready.
我們往往不同意 AdCom 的許多安排方式,包括所提出的問題;那可能是整個顧問決策流程中最糟的一部分,從投票後委員們的評論也可看出。不,我不認為接下來 12 天內會再有另一場 AdCom;但如果真的有,我想我們也會準備好。
Boobalan Pachaiyappan - Analyst
Boobalan Pachaiyappan - Analyst
All right. Maybe just one more very quickly. Let's just say you receive CRL, and then the FDA wants you to do another trial. What would you need to see in the FDA's feedback to justify additional investment, and what would the likely timeline could look like? Thank you.
好的。再很快問最後一個。假設你們收到 CRL,而 FDA 希望你們再做一項試驗。你們需要在 FDA 的回饋中看到什麼,才會合理化進一步投資?可能的時程會是什麼樣子?謝謝。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Yeah, that is a really important question, and it's one that we've been debating internally. If the FDA issues us a CRL, obviously, we will very carefully take in the information included in that CRL and what they ask for, and then we will make the decisions prudently based on if we think that there's a way to establish greater efficacy and/or safety doing another clinical trial.
是的,這是個非常重要的問題,也是我們內部一直在討論的。如果 FDA 給我們發出 CRL,顯然我們會非常仔細地吸收該 CRL 中包含的資訊以及他們要求的事項,然後我們會審慎做出決策,取決於我們是否認為透過另一項臨床試驗能建立更高的療效和/或安全性。
What I can tell you is we believe that Deramiocel works to make Duchenne less impactful to these boys and young men in terms of upper limb function. We've seen it year over year and in multiple clinical studies, and many independent peer reviewers have seen it as well. So, I'm reluctant to say goodbye to Deramiocel if it would require some simple clinical work that could further support it.
我能告訴你的是,我們相信 Deramiocel 的作用是讓杜興氏症(Duchenne)對這些男孩與年輕男性在上肢功能方面的影響降低。我們在多項臨床研究中逐年都看到了這點,許多獨立的同儕審查者也同樣看到了。因此,如果只需要一些相對簡單的臨床工作就能進一步支持它,我不太願意就此向 Deramiocel 道別。
Having said that, internally, we are focusing primarily on approval. We believe the FDA has enough data to make a positive decision and look forward to sharing that if and when it comes.
話雖如此,我們內部目前主要聚焦在取得核准。我們相信 FDA 已有足夠的數據做出正面決定,也期待在結果出來時(如果以及當它出來時)與大家分享。
Boobalan Pachaiyappan - Analyst
Boobalan Pachaiyappan - Analyst
Great. Thanks for taking our questions, and good luck.
很好。謝謝回答我們的問題,祝你好運。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thanks, Boobalan.
謝謝你,Boobalan。
Operator
Operator
I will now turn the call over to management for closing remarks.
我現在把電話交回管理團隊做結語。
Linda Marban - President, Chief Executive Officer and Director
Linda Marban - President, Chief Executive Officer and Director
Thank you so much for joining us today. Since the Advisory Committee Meeting in July, we have submitted the two-year open-label data from HOPE-3 to FDA, presented new results at the World Muscle Society and the American Heart Association. The validation of our work by our external review has continued to strengthen our confidence in the data.
非常感謝各位今天加入我們。自 7 月的諮詢委員會會議以來,我們已向 FDA 提交 HOPE-3 的兩年期開放標籤數據,並在世界肌肉學會(World Muscle Society)與美國心臟協會(American Heart Association)發表了新的結果。外部審查對我們工作的驗證,持續強化我們對這些數據的信心。
We recognize the urgent unmet need in Duchenne, but we are not asking for a pass because of it. We have run this program with rigor and transparency, and we believe the evidence stands on its own. We are encouraged by FDA's focus on rare disease, including the agency's recently launched Rare Disease Framework Initiative, which recognizes the challenge of developing therapies for small, heterogeneous patient populations like Duchenne. We appreciate FDA's engagement throughout this review, and we respect its process.
我們理解杜興氏症存在迫切且未被滿足的需求,但我們並不是因為這點就要求被放行。我們以嚴謹與透明的方式推動這個計畫,並相信證據本身就站得住腳。我們也受到 FDA 對罕見疾病的關注所鼓舞,包括該機構近期啟動的「罕見疾病框架倡議」(Rare Disease Framework Initiative),其認知到為像杜興氏症這樣規模小且異質性高的病患族群開發療法所面臨的挑戰。我們感謝 FDA 在整個審查過程中的投入,也尊重其流程。
To the Duchenne community, the patients, families, clinicians, and advocates, thank you, thank you, thank you. We hear you, and we are working tirelessly to bring Deramiocel to approval. You may now disconnect.
致杜興氏症社群、病患、家屬、臨床醫師與倡議者:謝謝、謝謝、謝謝。我們聽見你們的聲音,我們正不懈努力,推動 Deramiocel 取得核准。您現在可以掛線。
Operator
Operator
Ladies and gentlemen, this concludes our conference call for today. Thank you for your participation. You may now disconnect.
各位女士先生,我們今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。